Pharmaceutical Treatment of Fatigue After Aneurysmal Subarachnoid Hemorrhage

PHASE2CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

September 5, 2017

Primary Completion Date

September 13, 2019

Study Completion Date

September 13, 2019

Conditions
Aneurysmal Subarachnoid Hemorrhage
Interventions
DRUG

OSU 6162

All patients will receive a dose of OSU6162 15 mg BID x 2 per day. The expected duration of therapy is 12 weeks. After 1 week of treatment, patients who do not respond to treatment will have their dose increased to maximum 30 mg BID x 2 per day.

DRUG

Placebo Oral Tablet

All patients will receive a dose of placebo 15 mg BID x 2 per day. The expected duration of therapy is 12 weeks. After 1 week of treatment, patients who do not respond to treatment will have their dose increased to maximum 30 mg BID x 2 per day.

Trial Locations (1)

0027

Oslo University Hospital, Oslo

All Listed Sponsors
collaborator

Göteborg University

OTHER

collaborator

Sahlgrenska University Hospital

OTHER

lead

Oslo University Hospital

OTHER

NCT03209830 - Pharmaceutical Treatment of Fatigue After Aneurysmal Subarachnoid Hemorrhage | Biotech Hunter | Biotech Hunter